Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

including the California State Science Fair (April 2025), the national Thermo Fisher Scientific Junior Innovators Challenge (June 2025), and the Regeneron International Science & Engineering Fair ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

A drugmaker with one of the world's top-selling drugs Regeneron (NASDAQ: REGN) is a well-established biotech company that generates consistent revenue and profits. However, the drugmaker ...

On the bright side, Leerink Partners upgraded Regeneron to a “strong-buy,” proving at least one analyst still believes in scientific miracles and stock rebounds. Despite the lukewarm analyst sentiment ...

Leerink Partnrs also issued estimates for NeuroPace’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.51) EPS, FY2027 ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Regeneron Pharmaceuticals Inc REGN raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often ...

In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The company’s shares closed yesterday at $19.29.